Victory Capital Management Inc. Has $4.51 Million Stock Holdings in STAAR Surgical (NASDAQ:STAA)

Victory Capital Management Inc. trimmed its position in STAAR Surgical (NASDAQ:STAA) by 1.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,800 shares of the medical instruments supplier’s stock after selling 3,681 shares during the period. Victory Capital Management Inc. owned approximately 0.38% of STAAR Surgical worth $4,513,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. State Street Corp raised its position in shares of STAAR Surgical by 0.5% in the 3rd quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock valued at $72,092,000 after acquiring an additional 10,430 shares during the period. Geode Capital Management LLC raised its holdings in STAAR Surgical by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after buying an additional 31,212 shares during the period. Defender Capital LLC. raised its holdings in STAAR Surgical by 3.5% during the 4th quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after buying an additional 23,950 shares during the period. American Capital Management Inc. raised its holdings in STAAR Surgical by 42.9% during the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock worth $19,051,000 after buying an additional 154,037 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in STAAR Surgical by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 444,290 shares of the medical instruments supplier’s stock worth $10,792,000 after buying an additional 18,168 shares during the period. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. bought 23,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was acquired at an average cost of $24.33 per share, with a total value of $559,590.00. Following the completion of the purchase, the insider now owns 10,848,631 shares of the company’s stock, valued at $263,947,192.23. This represents a 0.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders bought 910,843 shares of company stock valued at $15,509,972. 1.00% of the stock is owned by corporate insiders.

STAAR Surgical Stock Down 2.1 %

Shares of STAA opened at $17.05 on Friday. The stock has a market capitalization of $840.99 million, a P/E ratio of -41.59 and a beta of 0.66. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The company has a 50 day moving average of $20.40 and a 200-day moving average of $26.17.

Wall Street Analysts Forecast Growth

STAA has been the topic of several research analyst reports. Stephens restated an “equal weight” rating and set a $28.00 target price on shares of STAAR Surgical in a report on Wednesday, February 12th. Piper Sandler dropped their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 12th. Mizuho downgraded shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $45.00 to $17.00 in a report on Wednesday, February 12th. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group dropped their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $26.86.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.